Effects of glucagon on adenosine 3',5'-monophosphate and guanosine 3',5'-monophosphate in human plasma and urine.
Glucagon, infused intravenously into fasting, well-hydrated, normal men in doses of 25-200 ng/kg per min, induced up to 30-fold increases in both plasma and urinary cyclic AMP. Cyclic GMP levels were unaffected by glucagon. Simultaneous cyclic AMP and inulin clearance studies demonstrated that the glucagon-induced increase in urinary cyclic AMP was entirely due to glomerular filtration of the elevated plasma levels of the nucleotide. The cyclic AMP response to glucagon was not mediated by parathyroid hormone or epinephrine, and trypsintreated glucagon was completely inactive. The perfused rat liver released cyclic AMP into the perfusate in response to glucagon, indicating that the liver is a possible source of the cyclic AMP entering the extracellular fluids in response to glucagon in vivo.
D000227:Adenine Nucleotides / Q000097:blood / Q000378:metabolism* / Q000652:urine; D000328:Adult; D004837:Epinephrine / Q000494:pharmacology; D005215:Fasting; D005934:Glucagon / Q000494:pharmacology*; D005947:Glucose / Q000494:pharmacology; D006150:Guanine Nucleotides / Q000097:blood / Q000378:metabolism* / Q000652:urine; D006801:Humans; D007275:Injections, Intravenous; D007328:Insulin / Q000494:pharmacology; D008099:Liver / Q000187:drug effects / Q000378:metabolism; D008297:Male; D010281:Parathyroid Hormone / Q000494:pharmacology; D010477:Perfusion; D014357:Trypsin / Q000494:pharmacology; D014361:Trypsin Inhibitors / Q000494:pharmacology
D000227:Adenine Nucleotides; D006150:Guanine Nucleotides; D007328:Insulin; D010281:Parathyroid Hormone; D014361:Trypsin Inhibitors; D005934:Glucagon; D014357:Trypsin; D005947:Glucose; D004837:Epinephrine